- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- January 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- November 2025
- 93 Pages
Global
From €5025EUR$5,600USD£4,410GBP
- Report
- November 2025
- 506 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2154EUR$2,400USD£1,890GBP
€2692EUR$3,000USD£2,363GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1077EUR$1,200USD£945GBP
€1346EUR$1,500USD£1,181GBP
- Report
- January 2025
- 194 Pages
Global
From €5707EUR$6,360USD£5,009GBP
€7134EUR$7,950USD£6,261GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1436EUR$1,600USD£1,260GBP
€1795EUR$2,000USD£1,575GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1436EUR$1,600USD£1,260GBP
€1795EUR$2,000USD£1,575GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1436EUR$1,600USD£1,260GBP
€1795EUR$2,000USD£1,575GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1077EUR$1,200USD£945GBP
€1346EUR$1,500USD£1,181GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1077EUR$1,200USD£945GBP
€1346EUR$1,500USD£1,181GBP
From €4397EUR$4,900USD£3,859GBP
- Report
- March 2025
- 180 Pages
Global
From €4038EUR$4,500USD£3,544GBP
- Report
- June 2025
- 209 Pages
Global
From €2243EUR$2,500USD£1,969GBP
- Report
- September 2025
- 150 Pages
Global
From €3455EUR$3,850USD£3,032GBP
- Report
- June 2025
- 150 Pages
Global
From €2422EUR$2,699USD£2,126GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2503EUR$2,789USD£2,196GBP
- Report
- June 2025
- 150 Pages
Global
From €2422EUR$2,699USD£2,126GBP
- Report
- June 2025
- 400 Pages
Global
From €4441EUR$4,949USD£3,898GBP

Levodopa is a drug used to treat Parkinson's disease, a neurological disorder that affects movement. It is a dopamine precursor, meaning it is converted into dopamine in the brain, which helps to reduce the symptoms of Parkinson's. Levodopa is usually taken in combination with other drugs, such as carbidopa, to increase its effectiveness. It is one of the most commonly prescribed drugs for Parkinson's, and is often the first line of treatment.
Levodopa is a part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. The CNS drug market is highly competitive, with many different companies offering various treatments.
Some of the companies in the Levodopa market include Merck, Novartis, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more